UK markets close in 6 hours 1 minute
  • FTSE 100

    7,097.18
    +23.12 (+0.33%)
     
  • FTSE 250

    22,626.88
    -32.54 (-0.14%)
     
  • AIM

    1,232.20
    +1.11 (+0.09%)
     
  • GBP/EUR

    1.1708
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.3965
    +0.0001 (+0.01%)
     
  • BTC-GBP

    23,841.43
    -638.69 (-2.61%)
     
  • CMC Crypto 200

    804.22
    -5.97 (-0.74%)
     
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • DOW

    33,874.24
    -71.34 (-0.21%)
     
  • CRUDE OIL

    73.30
    +0.22 (+0.30%)
     
  • GOLD FUTURES

    1,781.30
    -2.10 (-0.12%)
     
  • NIKKEI 225

    28,875.23
    +0.34 (+0.00%)
     
  • HANG SENG

    28,882.46
    +65.39 (+0.23%)
     
  • DAX

    15,590.12
    +133.73 (+0.87%)
     
  • CAC 40

    6,617.15
    +66.08 (+1.01%)
     

EU to decide on Astrazeneca's $39 billion Alexion deal by July 5

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: A company logo is seen at the AstraZeneca site in Macclesfield
  • Oops!
    Something went wrong.
    Please try again later.

BRUSSELS (Reuters) - EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.

AstraZeneca sought EU approval on Monday for the deal, its largest ever in a bet on rare-disease immunology and to boost its business, which includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.

The Commission can either clear the deal with or without conditions or it can open a four-month long investigation if it has serious concerns.

The UK Competition Authority and Markets Authority is also reviewing the bid which has already received the green light in the United States, Canada, Brazil and Russia.

(Reporting by Foo Yun Chee; editing by David Evans)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting